Understanding OCLM: Potential Drug Target Or Biomarker for Eye Diseases

Target Name: OCLM

NCBI ID: G10896

OCLM

Other Name(s): Trabecular meshwork-inducible stretch response protein | TISR | Trabecular meshwork inducible stretch response protein | Oculomedin

Understanding OCLM: Potential Drug Target Or Biomarker for Eye Diseases

OCLM, or Trabecular meshwork-inducible stretch response protein, is a protein that is expressed in the eye and has been shown to play a role in the development and progression of a number of eye diseases, including cataracts, glaucoma, and age-related macular degeneration (AMD). In recent years, researchers have been interested in using OCLM as a drug target or biomarker for these diseases, and several studies have investigated its potential utility in these areas.

One of the main reasons for the interest in OCLM is its unique structure and biology. OCLM is a protein that is composed of four domains: an N-terminus, a C-terminus, a middle transmembrane region, and a protein body. The protein body consists of a single polypeptide chain that is composed of 126 amino acids and has a calculated molecular weight of 13.9 kDa. The N-terminus of OCLM contains a unique farnesylated cysteine 鈥嬧?媟esidue, which is important for its stability and functions in the eye. The C -terminus of OCLM contains a conserved GXXGXXG repeat, which is known for its role in protein-protein interactions and may be involved in OCLM's localization and stability.

In addition to its unique structure, OCLM has also been shown to have unique functions in the eye. For example, studies have shown that OCLM is involved in the regulation of cell survival and proliferation in the retina, and that it plays a role in the development and progression of age-related macular degeneration (AMD). OCLM has also been shown to be involved in the regulation of angiogenesis, the formation of blood vessels in the retina, and the production of factors that promote blood vessel growth and proliferation.

Despite its potential as a drug target or biomarker, OCLM is still a relatively unstudied protein. There are currently no known drugs that are specifically targeting OCLM, and there are limited resources available for the study of OCLM-related diseases. However, as research continues to advance, it is likely that OCLM will become a valuable tool for the treatment of eye diseases.

In conclusion, OCLM is a protein that is expressed in the eye and has been shown to play a role in the development and progression of several eye diseases. Its unique structure and biology, as well as its functions in the eye, make it an attractive candidate for drug targeting or biomarker research. As research continues to advance, it is likely that OCLM will become a valuable tool for the treatment of eye diseases.

Protein Name: Oculomedin

The "OCLM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OCLM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets